8-K - NovaBay Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NovaBay Pharmaceuticals, Inc. announced on February 11, 2026, that its board approved a 1-for-5 reverse stock split pursuant to stockholder approval at the October 16, 2025 annual meeting. The split will be effective February 20, 2026, reducing outstanding shares from approximately 130,623,400 to 26,124,680 to help comply with NYSE American continued listing requirements.

Key Takeaways

1Board approved 1-for-5 reverse stock split on February 11, 2026

2Stockholder approval received at annual meeting on October 16, 2025

3Effective 4:15 p.m. New York City time on February 20, 2026

4Trading on split-adjusted basis begins February 23, 2026

5Reduces outstanding shares from 130,623,400 to approximately 26,124,680

6New CUSIP: 66987P 508; ticker NBY unchanged

7Exchange agent: Equiniti Trust Company, LLC

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events On February 11, 2026, pursuant to stockholder approval at the annual meeting on October 16, 2025, the board of directors of NovaBay Pharmaceuticals

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated February 11, 2026 104 Cover Page Interactive Data File (embe

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1